Introduction
============

Lynch syndrome (hereditary non-polyposis cancer) is an autosomal dominant disorder associated with germline mutations in one of four DNA mismatch repair genes. Approximately 90% of mutations are located in *MLH1* or *MSH2*, the remainder in *MSH6* and *PMS2*.[@b1-tcrm-13-915],[@b2-tcrm-13-915] Lynch syndrome carries increased risk of colorectal cancer, endometrial cancer and other epithelial malignancies.[@b1-tcrm-13-915]

Lynch syndrome classifications do not include thyroid cancer. The Amsterdam criteria apply the "3-2-1 Rule": three relatives with colorectal cancer, one a first degree relative of the other two; two successive generations affected; one diagnosed before the age of 50 years. The expanded Amsterdam II classification includes non-colorectal cancers: endometrial, small intestine, ureteric, or renal cancers.[@b3-tcrm-13-915]

This study reports a female with Lynch syndrome-related colon cancer that developed synchronous thyroid cancer and 6 years later breast cancer with progression to metastatic disease due to thyroid and breast cancer burden. The aim of this study was to determine whether the thyroid cancer could be genetically linked to the same mismatch repair gene mutation as her Lynch syndrome colonic cancer.

Case report
===========

Written informed consent was obtained from the patient's next of kin for publication of this case report and the associated images. A 58-year-old female with widespread, progressive meta static disease (breast, bowel, and thyroid cancer) was referred for advice on attribution of the metastatic burden to thyroid cancer and thyroid-specific intervention. Past history included metallic aortic valve replacement (at age 34 years) and aortic arch replacement (at age 52 years), and prophylactic total hysterectomy (at age 41 years). The family history included ovarian, endometrial, and colon cancer in several first-degree relatives.

Synchronous thyroid and colorectal malignancies were detected at 47 years. The cecal carcinoma (pT3pN0, 55×60×40 mm) showed absent expression of MSH2 and MSH6 protein in immunohistochemistry, consistent with a deficiency of DNA mismatch repair and Lynch syndrome. DNA analysis found an exon 6 sequence variation (c.998G\>A) in *MSH2* (as detected by semi-automated DNA sequencing and multiplex ligation probe amplification analysis).

Total thyroidectomy and neck dissection showed a 22×20×18 mm papillary thyroid carcinoma (PTC) with lymphovascular and striated muscle invasion and 2/2 lymph node metastases (pT2N1aMx). Progressive radioactive iodine doses and scans and the stimulated and unstimulated thyroglobulin levels are shown in [Figure 1A](#f1-tcrm-13-915){ref-type="fig"}. At 51 years, metastatic PTC was detected in locoregional cervical nodes, and modified radical neck dissection was undertaken.

Positron emission topography (PET) surveillance at 53 years showed breast fluorodeoxyglucose (FDG)-uptake. Biopsy showed an ER+/PR−/HER2− breast carcinoma. A pT2pN1a grade 2 infiltrating ductal carcinoma was excised and followed by adjuvant radiotherapy and tamoxifen.

At 56 years, a 2-FDG-avid lytic acromial lesion was identified. Biopsy showed poorly differentiated thyroid cancer. Acromial irradiation was undertaken. After 15 months, axillary lymph node tumor burden was evident; biopsy confirmed metastatic breast cancer. Contemporaneous unstimulated thyroglobulin levels were 4,260 µg/L (RR \<55 µg/L). Examestane and everolimus were commenced, the latter being trialed at the time for progressive hormone-refractory breast cancer and shown to have anti-thyroid cancer activity.[@b4-tcrm-13-915] Thyroglobulin declined ([Figure 1A](#f1-tcrm-13-915){ref-type="fig"}). Everolimus-associated complications necessitated dose reduction and cessation. Unstimulated thyroglobulin levels rose ([Figure 1A](#f1-tcrm-13-915){ref-type="fig"}). Progressive widespread metastatic disease was evident ([Figure 1B](#f1-tcrm-13-915){ref-type="fig"}). Retrospective molecular analysis of the primary PTC identified a *BRAF V600E* mutation. Immunohistochemistry on the primary PTC showed normal *MSH2* and *MSH6* gene expression.

As some of the metastatic burden was thyroid cancer related, 5.6 GBq I^131^ was administered; the unstimulated thyroglobulin level after 4 weeks was 221 µg/L ([Figure 1A](#f1-tcrm-13-915){ref-type="fig"}). The tyrosine kinase inhibitor sorafenib was then commenced. The patient died after 3 months from disseminated leptomeningeal metastases.

Discussion
==========

This study presents a fascinating case of a young woman with Lynch syndrome-related colonic cancer with synchronous papillary thyroid cancer and metachronous breast cancer with progression to metastatic disease related to both thyroid and breast cancers.

Thyroid cancer generally has an excellent long-term prognosis. Mutations in *BRAF*, *RET*/PTC, *NTRK1*, or *RAS* have been reported in up to 70% of differentiated thyroid cancers.[@b5-tcrm-13-915] *BRAF* mutation confers a more aggressive clinical course, as evident in this case.

This is the third case of thyroid cancer described in Lynch syndrome. The first case was a female from a Lynch syndrome pedigree with a germline *MSH2* mutation who developed an undifferentiated thyroid cancer as the index cancer. Immunohistochemistry showed that MSH2 expression was absent.[@b1-tcrm-13-915] The second case was a female from a Lynch syndrome pedigree with anaplastic thyroid cancer as the index cancer. Immunochemistry also showed that MSH2 expression was absent.[@b2-tcrm-13-915] Genetic analysis confirmed a germline mutation in case 1 and in family members of case 2.

The present case demonstrated loss of MSH2 and MSH6 staining in her colonic cancer only. Lynch syndrome was confirmed by DNA sequencing of *MSH2* that revealed a c.998G\>A missense change in exon 6. In this case, the PTC displayed normal mismatch repair protein expression and showed a *BRAF* mutation, making it unlikely for mismatch repair defects due to the cancer genetics of Lynch syndrome. *MSH2* promoter hypermethylation has been shown to occur in colorectal cancers related to Lynch syndrome, with somatic inactivation of the remaining wild-type allele.[@b6-tcrm-13-915]

Second, primary tumors, synchronous or metachronous, have been reported in literature.[@b7-tcrm-13-915] It is hypothesized that the synchronous occurrence of two tumors may be a result of a mutagenic trigger that causes independent genetic events[@b7-tcrm-13-915] and that metachronous tumors may be due to persisting effects of genetic and behavioral risk factors.[@b7-tcrm-13-915] It is possible the thyroid gland may be activated by prior hormone-secreting cancers with overstimulation in a reactive autoimmune environment, as hypothesized by Sisti et al.[@b8-tcrm-13-915] Furthermore, a history of thyroid cancer is associated with the increased risk of developing breast cancer, and several studies have evaluated the thyroid hormone and proposed mechanisms for activation of the associated oncogene.[@b9-tcrm-13-915] The most likely explanation for synchronous cancers in the present case seems to be a sporadic thyroid cancer on a background of genetic cancer predisposition.

It should be noted that normal immunohistochemistry does not completely exclude the mismatch repair defects that characterize Lynch syndrome. False negatives may occur due to the following reasons: First, the effectiveness of immunohistochemistry in revealing germline mismatch repair mutations depends on the number of antibodies used. Mismatch repair proteins form heterodimers to maintain function: MSH2 with MSH6; MHL2 with PMS2. Immunohistochemistry with MLH1/MSH2 antibodies has a sensitivity of 85% in detecting a mismatch repair mutation; sensitivity is increased to 92% using PMS2 and MSH6 antibodies.[@b10-tcrm-13-915] Furthermore, if immunohistochemistry is performed with MLH1/MSH2 antibodies only, some MLH1 and MSH2 abnormalities may be missed, as some pathogenic mutations retain protein expression. Second, not all pathogenic mutations result in loss of protein by immunohistochemistry. Immunohistochemistry is effective in screening for mutations due to a truncated or degraded protein, but performs poorly in differentiating abnormal protein due to a missense mutation from normal protein. Greater than 30% of *MLH1* mutations are missense mutations that may not be detected by immunohistochemistry. Third, there may be a misleadingly false normal staining pattern due to a second hit that inactivates the wild-type allele resulting in non-functional protein but allowing normal antibody binding.[@b10-tcrm-13-915] Immunohistochemistry with a four antibody panel and microsatellite instability (MSI) testing have similar sensitivity for detecting mismatch repair mutations; however, each may miss cases detectable by the other method. Therefore, if high clinical suspicion synchronous cancers may be linked to the same pathogenic process, normal immunohistochemistry result should be verified with MSI testing.

These few cases raise the importance of considering individual cancer genetics in familial cancer syndromes, particularly when other cancers do not fit the described syndrome. Careful documentation of other malignancies in patients with thyroid cancer and their families would assist in better understanding any potential association of thyroid cancer to known familial cancer syndromes. Appropriate genetic testing of the cancers will clarify whether common genetics explain synchronous or subsequent malignancies in individuals and their families and add to greater understanding of the genetic mechanisms that may explain apparently unrelated cancers.
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![(**A**) The time course in years of the patient's illness, with stimulated thyroglobulin levels (\--•\--), unstimulated thyroglobulin levels (\--♦\--), radioactive iodine therapy doses (RAI, 5.5 GBq each dose), I^131^ scan intervals and results (+ indicating tracer uptake and N no tracer uptake), and timing and duration of examestane, everolimus, and sorafenib. (**B**) The bone scan performed at 57 years, demonstrating metastatic bone disease with increased tracer uptake in the sternum, right 5th and 6th ribs, left scapula, right anterior superior iliac spine and intertrochanteric region of proximal left femur.](tcrm-13-915Fig1){#f1-tcrm-13-915}
